Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Are you taking 400 MG or more of Celebrex a day?

Have any of the following side effects occurred? (Please check all that apply.)

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Celebrex Lawsuit

Celebrex Side Effects Lawsuits | Side Effects: Heart Attack, Cardiovascular Problems, Blood Clots, Strokes

Celebrex Side Effects May Link To Heart Attack Lawsuits

Celebrex | Lawsuit, Lawyer | Side Effects: Heart Attack, Cardiovascular Problems, Blood Clots, Strokes

Celebrex Lawsuit

Celebrex (Generic: Celecoxib) is a COX-2 inhibitor, a class of drugs linked to an increased risk of blood clots, heart attacks and strokes. Celebrex is the only COX-2 inhibitor still on the market in the United States. Celebrex and the recently withdrawn Bextra are both marketed by the Pharmacia Corporation and Pfizer Inc. in the United States. Celebrex and the other COX-2 inhibitors are prescribed for the treatment of osteoarthritis, adult rheumatoid arthritis, and the pain associated with menstrual cramping.

FDA Asked To Examine The COX-2

In February 2005, the FDA asked advisory committees to examine the COX-2 inhibitors and to determine whether they offer enough benefits to stay on the market, whether they need stronger warnings, and what further research on the drugs is needed. The advisers met from February 16, 2005 through February 18, 2005. Studies strongly suggest the entire class of drugs called COX-2 inhibitors elevates the chances of cardiovascular problems, Dr. Ned Braunstein, senior director of Merck Research Laboratories told the panel of FDA advisers.The hearings concluded and both Celebrex and Bextra were allowed to stay on the market. However, on April 7 the FDA asked Pfizer to withdraw Bextra from the market, citing reports of cardiovascular events and allergic skin reactions. When Pfizer agreed to suspend sales of Bextra, Celebrex became the last COX-2 inhibitor to remain on the market.

A study from the Cleveland Clinic appeared in the Journal of the American Medical Association and was based on an analysis of previous clinical trials. In a study of more than 8,000 patients that compared the COX-2 inhibitor rofecoxib (Vioxx) with the traditional NSAID naproxen, the risk of cardiovascular problems, including heart attack, chest pain related to heart disease, stroke, sudden death and blood clots, was more than two times higher in the rofecoxib group than in the naproxen group. Merck voluntarily withdrew Vioxx in September 2004 after a study found that the drug doubled the risk of heart attack and stroke in patients who took it for at least 18 months. Following the Vioxx recall, questions arose about Celebrex, Bextra, and non-prescription pain relievers such as Naproxen (Aleve).

Celebrex may increase risk of heart attacks and lead to strokes

Dr. Garret Fitzgerald, a top scientist and COX-2 researcher at the University of Pennsylvania, told the US regulatory panel that all pain drugs in the class known as COX-2 inhibitors increase the risk of heart attacks and strokes. Dr. Fitzgerald has said that the body reacts in the same way to drugs including Merck's Vioxx and Pfizer's Celebrex and Bextra. Dr. Fitzgerald said the drugs create an imbalance in the body's cardiovascular system that leads to an increased risk of heart attacks and strokes.

The annual rates of heart attack in both the Celebrex (celecoxib) and Vioxx (rofecoxib) studies were increased compared to a review of studies containing a total of more than 48,000 patients. In those studies, 0.52% of patients taking an inactive placebo pill had a heart attack each year. The annual rate of heart attack was 0.74% for patients taking rofecoxib and 0.80% for those taking celecoxib.

On March 1, 2006, a group of researchers in New Zealand said that a reanalysis of older studies conducted on Pfizer's pain reliever Celebrex show the drug can raise the risk of suffering a heart attack. Researchers from New Zealand's Medical Research Institute in Wellington said that the analysis, which used data from past Celebrex clinical trials, showed the drug could nearly double the risk of heart attack in patients, according to local reports.

The analysis utilized data from six studies on Celebrex involving 12,780 users. The results were published in the Journal of the Royal Society of Medicine.

Pfizer has said it expects 2006 sales of Celebrex to be in excess of $2 billion.

Need Legal Help Regarding Celebrex Side Effects?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).



Celebrex LawsuitRSS Feed

Doctor Accused of Falsifying Drug Studies Pleads Guilty

Feb 23, 2010 | Parker Waichman LLP
Dr. Scott S. Reuben, former chief of acute pain at the Bay State Hospital in Springfield, Massachusetts, has pleaded guilty to one count of health care fraud. As we’ve reported previously, Reuben was charged in federal court last month with falsifying studies involving the post-surgical benefits of drugs like Vioxx, Bextra, Celebrex, Effexor and Lyrica. According to the Associated Press, federal prosecutors in Massachusetts had alleged that Reuben sought and received research grants from...

Baystate Medical Center Subpoenaed Over Fake Drug Studies

Apr 8, 2009 | Parker Waichman LLP
The Baystate Medical Center has received a subpoena as part of a federal investigation into a doctor there who falsified 21 drug studies.  activity As we reported last month, medical journals have been asked to retract studies involving Vioxx, Celebrex, Lyrica and other drugs.  All of the studies were published between 1996 and 2008. According to The Wall Street Journal, the journal Anesthesia & Analgesia has retracted 10 studies. It also posted a list of 11 others that were...

Researcher Faked Data for 21 Studies Involving Vioxx, Celebrex and Other Drugs

Mar 11, 2009 | Parker Waichman LLP
Medical journals have been asked to retract 21 studies that touted the benefits of Vioxx, Celebrex and other drugs.  According to The Wall Street Journal, Baystate Medical Center, Springfield, Mass. is asking the journals to make the retractions because its former chief of acute pain, Dr. Scott S. Reuben, had faked data used in the studies.In addition to Vioxx and Celebrex, some of the 21 studies involved the fibromyalgia drug Lyrica and the antidepressant Effexor XR.   Reuben's...

Vioxx, Celebrex, Other Painkillers Up Risks for Heart Failure, Heart Attack Patients

Nov 12, 2008 | Parker Waichman LLP
Vioxx, Celebrex, ibuprofen and other NSAID painkillers increase the chances that heart attack and heart failure patients will experience a second heart attack or death, a new study says.  According to Danish researchers, the risk of a second heart attack or death actually doubled within the first 90 days of starting Vioxx or Celebrex.  Other painkillers, like ibuprofen, increased the risk between 2.1 and 1.3 times. The study was presented this week at the American Heart Association...

COX-2 Inhibitors More Likely to Raise Heart Risks Than Other NSAIDs

Nov 5, 2008 | Parker Waichman LLP
A new study that confirms the heart risks associated with a class of drugs called NSAIDs has found that the increased risk correlates to the specific pain-causing molecule they act against.   According to the study, NSAIDS that are cox-2 inhibitors are more likely to increase the risks of heart attacks and strokes. NSAIDs  are the most prescribed medications for treating conditions such as arthritis. Most people are familiar with over-the-counter, nonprescription NSAIDs, such as...

More Celebrex Lawsuit News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo